Avita Medical, Inc. - Common Stock (RCEL)
16.63
+0.95 (6.06%)
NASDAQ · Last Trade: Nov 6th, 2:48 PM EST
News & Press Releases
AVITA Medical (RCEL) Q3 2026 Earnings Call Transcriptfool.com
Going concern warning removed as revenue jumps and guidance rises again.
Via The Motley Fool · November 6, 2026
Avita Medical Q3 Earnings Call Highlightsmarketbeat.com
Avita Medical (NASDAQ:RCEL) raised its full-year revenue forecast for the second consecutive quarter after third-quarter sales rose 53% from a year earlier, driven by demand for its RECELL wound treatment system and growing adoption of Cohealyx.
The company reported revenue of $26.1 million, up fro
Via MarketBeat · November 6, 2026
AVITA Medical (NASDAQ:RCEL) Posts Q3 Beat and Raises 2026 Revenue Guidancechartmill.com
Via Chartmill · November 5, 2026
After-Hours Market Movers for Nov. 5, 2026: Gainers and Loserschartmill.com
Via Chartmill · November 5, 2026
Avita Medical (NASDAQ:RCEL) Beats Q2 Estimates and Raises Full-Year Guidancechartmill.com
Via Chartmill · August 6, 2026
AVITA Medical Reports Third Quarter Results
Delivers Strong Q3 With 53% Year-Over-Year Revenue Growth Raises Full Year 2026 Revenue Guidance
By AVITA Medical · Via GlobeNewswire · November 5, 2026
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced that the Centers for Medicare & Medicaid Services (CMS) has finalized national physician valuations for skin cell suspension autograft (SCSA) procedures performed using RECELL® under the Calendar Year 2027 Medicare Physician Fee Schedule.
By AVITA Medical · Via GlobeNewswire · November 5, 2026
AVITA Medical to Announce Third Quarter 2026 Financial Results
VALENCIA, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2026 financial results after the close of the U.S. financial markets on Thursday, November 5, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, November 6, 2026, at 8:30 a.m. Australian Eastern Daylight Time) to discuss its financial results and recent business highlights.
By AVITA Medical · Via GlobeNewswire · October 20, 2026
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
VALENCIA, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced that its senior management will participate in the following investor conferences:
By AVITA Medical · Via GlobeNewswire · September 2, 2026
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograftmarketbeat.com
Avita Medical (NASDAQ:RCEL) presented results from its PermeaDerm-I study, a randomized controlled trial evaluating PermeaDerm as temporary wound coverage following excision and before split-thickness skin grafting, compared with cadaveric allograft.
During a key opinion leader webinar, the company
Via MarketBeat · August 19, 2026
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
VALENCIA, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company, today announced positive results from its multicenter, randomized controlled PermeaDerm-I clinical study demonstrating PermeaDerm®, a biosynthetic wound matrix, delivered clinically comparable outcomes to cadaveric allograft while reducing product cost by 70%.
By AVITA Medical · Via GlobeNewswire · August 18, 2026
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%marketbeat.com
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 13% sequentially from $19.3 million in the first quarter and 18% from $18.4 million a year earlier, as the wound-care company cited growth across its product portfolio and in U.S. and international markets.
Presid
Via MarketBeat · August 16, 2026
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Buildsmarketbeat.com
Avita Medical (NASDAQ:RCEL) expects continued sequential revenue growth and aims to reach cash flow breakeven in the fourth quarter of 2025, President and CEO Cary Vance said at the Canaccord 46th Annual Boston Growth Conference.
Vance, who has been CEO for about 10 months after previously serving
Via MarketBeat · August 16, 2026
AVITA Medical (RCEL) Q2 2026 Earnings Call Transcriptfool.com
Revenue exceeded $21.7 million with guidance raised to $86M–$89M for full year.
Via The Motley Fool · August 13, 2026
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Aug. 09, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on August 12, 2026, at 4:00 p.m. Pacific Time (August 13, 2026, at 9:00 a.m. Australian Eastern Standard Time).
By AVITA Medical · Via GlobeNewswire · August 9, 2026
12 Health Care Stocks Moving In Friday's Intraday Sessionbenzinga.com
Gainers AVITA Medical (NASDAQ:RCEL) stock rose 58.4% to $7.53 during Friday's regular session. The company's market cap stands at $146.1 million. As per the press release, Q2 earnings came out yesterday.
Via Benzinga · August 7, 2026
What's going on in today's sessionchartmill.com
Via Chartmill · August 7, 2026
Which stocks are gapping on Friday?chartmill.com
Via Chartmill · August 7, 2026
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
VALENCIA, Calif., Aug. 07, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced it will be participating at the Canaccord Genuity 46th Annual Growth Conference in Boston, taking place August 11–13, 2026.
By AVITA Medical · Via GlobeNewswire · August 7, 2026
Avita Medical Q2 Earnings Call Highlightsmarketbeat.com
Avita Medical (NASDAQ:RCEL) reported second-quarter 2026 revenue of $21.7 million, up 18% from a year earlier and 13% sequentially, as growth in its RECELL wound-care product and newer portfolio offerings supported results.
President and Chief Executive Officer Cary Vance said the company’s U.S. RE
Via MarketBeat · August 7, 2026
AVITA Medical Reports Second Quarter Results, Raises 2026 Revenue Guidance, and Expects Fourth Quarter Cash Flow Breakeven
VALENCIA, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- AVITA Medical®, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,” or the “Company”), today reported financial results for the second quarter ended June 30, 2026.
By AVITA Medical · Via GlobeNewswire · August 6, 2026
AVITA Medical to Announce Second Quarter 2026 Financial Results
VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its second quarter 2026 financial results after the close of the U.S. financial markets on Thursday, August 6, 2026. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Friday, August 7, 2026, at 6:30 a.m. Australian Eastern Standard Time) to discuss its financial results and recent business highlights.
By AVITA Medical · Via GlobeNewswire · July 14, 2026
12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Gainers AVITA Medical (NASDAQ:RCEL) stock moved upwards by 11.1% to $4.9 during Thursday's after-market session. The market value of their outstanding shares is at $143.1 million. Lisata Therapeutics (NASDAQ:LSTA)
Via Benzinga · July 9, 2026
AVITA Medical Highlights First U.K. Clinical Experience with RECELL GO at British Burn Association Annual Meeting
VALENCIA, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, today announced the presentation of new clinical data highlighting the first documented use of RECELL GO in the United Kingdom (U.K.) at the 2026 British Burn Association (BBA) Annual Meeting in Nottingham, U.K.
By AVITA Medical · Via GlobeNewswire · June 18, 2026
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Cary Vance, President and Chief Executive Officer, and David O’Toole, Chief Financial Officer, on May 20, 2026, at 4:00 p.m. Pacific Time (May 21, 2026, at 9:00 a.m. Australian Eastern Standard Time).
By AVITA Medical · Via GlobeNewswire · May 17, 2026